Additionally, 6 stop‐gain and 2 nonsynonymous CH mutations in MLH1, MSH2 and PMS2 that might lead to mismatch repair deficiency (dMMR) were identified in 8 patients, and these confusions would result in unsuccessful immunotherapy using pembrolizumab. This evidence concerns the gene PMS2 and mismatch repair cancer syndrome 1.